As you might expect, the competition to win a share of the expanding GLP-1 market is fierce right now, with giants Novo ...

A new University of California San Diego study offers compelling evidence that glucagon-like peptide-1 (GLP-1) receptor ...

WASHINGTON -- Treatment with the investigational GLP-1/glucagon dual receptor agonist pemvidutide led to resolution of ...

The agreements with pharma giants Eli Lilly and Novo Nordisk could bring the price of the GLP-1 injectables from roughly ...

GLP-1 receptor agonists — the drug class that includes Ozempic, Wegovy and Mounjaro — were linked to improved survival among colon cancer patients in a new observational study from UC San Diego.

In youth newly diagnosed with type 2 diabetes, GLP-1–based therapies, including semaglutide and tirzepatide, achieved similar ...

Three new Cochrane reviews find evidence that GLP-1 drugs lead to clinically meaningful weight loss, though industry-funded ...

Novo Nordisk and Eli Lilly reached deals to lower GLP-1 drug costs for Medicare and Medicaid patients under Trump’s new ...

President Trump hailed his deal with pharma companies on GLP-1 drug pricing. The question is how big of a difference the deal ...

"GLP-1 drugs: a perfect-storm game-changer for food or just a crosswind?" was originally created and published by Just Food, ...

The rise of GLP-1 weight loss drugs has been a game-changer for the grocery sector, and the dairy segment appears ...

For long-term investors, there are plenty of reasons to buy and hold Eli Lilly for not only years but decades.